Tumor necrosis factor alpha (TNF- α) inhibitors are widely employed for the management of chronic inflammatory rheumatism. However, their usage carries significant risks, including site and infusion reactions, serious infections, malignancy, heart failure autoimmune and
demyelinating disorders. These risks are comprehensively outlined in risk management plans
(RMPs) associated with these molecules. RMP provides information on the safety profile of a
medicinal product as well as the measures that will be taken to minimize risks; these are known
as risk minimization measures. These measures are divided into routine measures related to elements, such as the summary of product characteristics, labeling, pack size, package leaflet, or
legal supply status of the product, while additional measures may include educational programs,
including tools for healthcare providers and patients, controlled access or pregnancy prevention
programs, among others. Additional measures can consist of one or more interventions that need
to be implemented in a sustainable way in a defined target group, while respecting the timing
and frequency of any intervention and procedures to reach the target population. An evaluation
of the effectiveness of these measures is required to determine whether or not an intervention
has been effective. This comprehensive review offers an in-depth exploration of the current
treatment, uses, and associated risks of TNF-α inhibitors. Additionally, it provides a detailed account of risk minimization measures and risk management practices while shedding light on
their real-world implementation and effectiveness.